Global recombinant DNA technology market is estimated to be valued at USD 172.94 Bn in 2024 and is expected to exhibit a CAGR of 9.6% during the forecast period (2024-2031). Recombinant DNA technology is the joining together of DNA molecules from two different sources into one molecule that can replicate and direct the assembly of its own components or related proteins. This process involves physically combining and interweaving two different strands of DNA through the use of restriction enzymes, DNA ligases and reverse transcriptase. In recent years, recombinant DNA technology has proven to be a revolutionary advancement in the field of genetics and biotechnology with wide ranging applications in drug development, research, and agriculture. This technology allows for the production of human proteins and medicines in much larger quantities than traditional extraction methods. It is also being used to develop new treatments for currently incurable diseases and to enhance crop yields. With growing demand across industries, the recombinant DNA technology market is poised to grow significantly in the coming years.

Market Dynamics:

The recombinant DNA technology market is driven by several factors such as increasing R&D activities in pharmaceutical and biotech industries, rising prevalence of chronic diseases, growing demand for genetic engineering, and gene therapy. The demand for affordable healthcare and therapeutic solutions combined with technological advancements in DNA analysis and sequencing techniques are also fueling the market growth. However, the market growth can be restricted due to high costs associated with development and stringent regulations for clinical trials. Moreover, ethical issues regarding germline gene editing may hamper market expansion to some extent. On the flip side, rising healthcare expenditures in emerging nations offer lucrative opportunities for key players. In addition, the growing acceptance of genetically modified crops for agriculture applications is expected to create new revenue pockets in the forthcoming years.

Key Features of the Study:

• This report provides an in-depth analysis of the global recombinant DNA technology market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global recombinant DNA technology market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes Thermo Fisher Scientific, Inc., Biogen, Inc., Sanofi , Pfizer, Inc., Amgen, Inc., Merck & Co., Inc., Profacgen, Monsanto Company, Genentech Inc., Eli Lilly and Company, Janssen Pharmaceuticals Inc., GSK plc., Jiangsu Recbio Technology Co., Ltd., New England Biolabs, GenScript, Lonza, and ProteoGenix.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global recombinant DNA technology market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global recombinant DNA technology market.

Detailed Segmentation-

• By Product Type:
  • Recombinant Protein Drugs
  • Vaccines
  • Genetically Modified Crops
  • Cell and Gene Therapy
  • Gene Editing
• By Application:
  • Therapeutics
  • Agriculture
  • Research
  • Others
• By End User:
  • Biotechnology and Pharmaceutical Company
  • Diagnostic Laboratories
  • Academic and Government Laboratories
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Company Profiles:

• Thermo Fisher Scientific, Inc.
• Biogen, Inc.
• Sanofi 
• Pfizer, Inc.
• Amgen, Inc.
• Merck & Co., Inc.
• Profacgen
• Monsanto Company
• Genentech Inc.
• Eli Lilly and Company
• Janssen Pharmaceuticals Inc.
• GSK plc.
• Jiangsu Recbio Technology Co., Ltd.
• New England Biolabs
• GenScript
• Lonza
• ProteoGenix